You are here

  • Home
  • Archive
  • Volume 3, Issue 2
  • Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2

Citation Tools

Article menu

Download PDFPDF

Spondyloarthritis
Original article
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Marzo-Ortega H, Sieper J, Kivitz A on behalf of the MEASURE 2 study group, et al
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
RMD Open 2017;3:e000592. doi: 10.1136/rmdopen-2017-000592